乾癬性關節炎 (PA) :競爭情形
Psoriatic Arthritis: Competitive Landscape to 2026
|出版日期||內容資訊||英文 48 Pages
|乾癬性關節炎 (PA) :競爭情形 Psoriatic Arthritis: Competitive Landscape to 2026|
|出版日期: 2018年12月19日||內容資訊: 英文 48 Pages||
乾癬性關節炎 (PA) 治療藥市場，也可利用皮下治療和靜脈內治療，也包含低分子口服藥和生物相似藥，競爭日益變得激烈。
本報告提供乾癬性關節炎 (PA) 治療藥調查分析，開發平台的評估，臨床實驗的評估，商業性的評估，競爭情形分析相關的系統性資訊。
The Psoriatic Arthritis (PsA) market has become increasingly competitive, with both subcutaneous and intravenous therapies being available as well as two oral small molecule and biosimilars. However, J&J and AbbVie are slated to remain headliners in the psoriatic arthritis marketplace, looking to capitalize on the excitement surrounding interleukin inhibitors and janus kinase inhibitors.
J&J and AbbVie have been the dominant players in the psoriatic arthritis market since the introduction of Remicade (2004) and Humira (2005) as the second and third TNF inhibitors approved by the FDA, respectively. AbbVie and J&J have launched or are developing biologics with novel mechanisms of action, including interleukin inhibitors, maintaining their position in the psoriatic arthritis space.
Diagnosed prevalence cases of psoriatic arthritis is expected to grow across each of the 8MM (United States, Japan, Australia, United Kingdom, France, Italy, Germany, Spain). The US will have the largest growth with almost 470,000 diagnosed prevalent cases in 2016, growing at an AGR of 5.36% to 2026.
It is found that industry sponsors are responsible for over 70% of psoriatic arthritis clinical trials, with the top seven industry sponsors accounting for 64% of all industry sponsored trials. Of these AbbVie and Johnson & Johnson (J&J) are responsible for 47 of the 121 industry sponsored clinical trials in the psoriatic arthritis space.
The report "Psoriatic Arthritis: Competitive Landscape to 2026", provides an assessment of the pipeline, clinical, and commercial landscape of psoriatic arthritis. Overall, it is expected that new drug approvals to drive market growth over the next decade (2016-2026).